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Abstract: Among matrix metalloproteinases (MMPs), the subfamily of gelatinases (MMP-2, MMP-9) is of 
particular interest due to their ability to degrade type IV collagen and other non-fibrillar collagen domains and 
proteins such as fibronectin and laminin. Whilst malignant cells often over-express various MMPs, the 
gelatinases have been most consistently detected in malignant tissues and associated with tumor growth, 
metastatic potential and angiogenesis. Radiosynthesis of carboxylic (1') and hydroxamic (2') MMPIs resulted in 
radiochemical yields of 70 ± 5% (n = 6) and 60 ± 5% (n = 4), respectively. Evaluation in A549-inoculated 
athymic mice showed a tumor uptake of 2.0 ± 0.7% ID/g (3 h p.i.), a tumor/blood ratio of 0.5 and a 
tumor/muscle ratio of 4.6 at 48 hp.i. for 1'. For compound 2' a tumor uptake of 0.7 + 0.2% ID/g (3 h p.i.), a 
tumor/blood ratio of 1.2 and a tumor/muscle ratio of 1.8 at 24 h p.i. were observed. HPLC analysis of the blood 
(plasma) showed no dehalogenation or other metabolites of 1' 2 h p.i. For compound 2', 65.4% of intact 
compound was found in the blood (plasma) and one polar metabolite (31%) was detected whereas in the tumor 
91.8% of the accumulated activity was caused by intact compound and only 8.1% by the metabolite. Planar 
imaging, using a Toshiba GCA-9300A/hg SPECT camera, showed that tumor tissue could be visualized and that 
image quality improved by decreasing specific activity resulting in lower liver uptake, indicating some degree of 
saturable binding in the liver. In vivo evaluation of these radioiodinated carboxylic and hydroxamic MMP 
inhibitor tracers revealed that MMP inhibitors could have potential as tumor imaging agents, but that further 
research is necessary. 
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1. Introduction 
Matrix metalloproteinases (MMPs) are a family of endopeptidases comprising over 20 enzyme subtypes that 
degrade extracellular matrix (Edwards and Murphy, 1998). Their activities are tightly controlled at the levels of 
gene transcription, zymogen activation by proteolysis and inhibition of active forms by the tissue inhibitors of 
matrix metalloproteinases (TIMPs) (Edwards et al., 1996). Among MMPs , the subfamily of gelatinases (MMP-
2, MMP-9) is of particular interest due to their ability to degrade type IV collagen and other non-fibrillar 
collagen domains and also proteins such as fibronectin and laminin. Whilst malignant cells often over-express 
various MMPs, the gelatinases have been most consistently detected in malignant tissues and associated with 
tumor growth, metastatic potential and angiogenesis (Edwards et al., 1996; Bernhard et al., 1994; Davies et al., 
1993; Heppner et al., 1996; Kossakowska et al., 1992; MacDougall and Matrisian, 1995; Bremer et al., 2001; 
Fang et al., 2000; Murray et al., 1996; Folkman, 1997; Rudek et al, 2002). 
Examples of peptidic and non-peptidic MMP inhibitors have proliferated in the literature over the last several 
years, with the vast majority of these compounds bearing a hydroxamic acid moiety as the requisite zinc-binding 
ligand. Other zinc-binding ligands that have been utilized include reverse hydroxamic acids, carboxylic acids, 
thiols, and thiadiazoles (Skiles et al., 2001). Tryptophane-based biphenylsulphonamide matrix metalloproteinase 
inhibitors were synthesized, evaluated in vitro; in vivo and as imaging agent and were published previously 
(Oltenfreiter et al., 2004, 2005a). Structural changes made to the biphenyl ring system, the α-position to 
carboxylic acid and the carboxylate moiety, have an influence on biological activity (O'Brien et al., 2000). 
Earlier experiments and SAR studies showed that biphenylsulfonamides substituted with bromine in the             
4'-position significantly improved the in vitro activity and exhibited superior pharmacokinetics (Cmax, t1/2, AUCs) 
relative to the compounds without bromine (Skiles et al., 2001). Halogens appended to the 4'-position of the 
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biphenyl ring, in general, increased potency against some MMPs. The magnitude of the increase did not change 
as the size of the halo substituent was increased from F to Cl to Br. On the other hand varying the lipophilicity of 
the α-position in general, maintained potency but decreased the oral bioavailability and significantly influenced 
the pharmacokinetic activity of the compounds. Replacement of for example an isobutyl group with smaller, less 
lipophilic substituents (methyl, hydrogen) or with a larger, more lipophilic group (benzyl) diminished the Cmax, 
t1/2, and AUCs relative to the analogues with the isobutyl group. Incorporation of side chains bearing larger 
substituents gave compounds that, in general, were poorly absorbed (O'Brien et al., 2000). It has also been 
shown that although carboxylates exhibit weaker zinc binding properties than hydroxamic acids, they are known 
to show a better oral bioavailability and are less prone to metabolic degradation (Kontogiorgis et al., 2005). 
In addition to potency and bioavailability, the issue of the desired selectivity profile for MMP inhibition remains 
an unresolved problem. Since MMP activity is an integral part of normal tissue remodelling, the possibility 
exists that the inhibition of particular MMPs would be detrimental and dose-limiting in a clinical setting. Dose-
related side effects include arthralgia and body aches. The origin of these musculoskeletal side effects is at 
present undetermined, although several hypotheses have been put forth. Both the inhibition of MMP-1 and the 
inhibition of tumor necrosis   factor   (TNF)   receptor   shedding   have   been proposed as mechanisms for the 
origin of this troublesome complication (Skiles et al., 2001). Taking these reflections into account the Valine 
analogues of the earlier published Tryptophane-based biphenylsulphonamide matrix metalloproteinase inhibitors 
have been synthesized and evaluated. By synthesis of the analogues we aimed at producing different selectivity 
profiles, biological activity and pharmacokinetic properties. 
This study reports on the biodistribution of iodine-123 labeled biphenylsulphonamide analogues, developed from 
structure-activity data of compounds with low nanomolar IC50 potencies for gelatinases (Tamura et al., 1998; 
Hanessian et al., 2001). These compounds were synthesized via a modified method obtained from the literature 
(Oltenfreiter et al., 2004; O'Brien et al., 2000; Tamura et al., 1998; Hanessian et al., 2001; Oltenfreiter et al., 
2005b), and evaluated in A549-inoculated mice. Metabolic studies were performed and their suitability as 
diagnostic agents evaluated. 
2. Materials and methods 
2.1.   General 
Synthesis, radiosynthesis and determination of biological activity of biphenylsulphonamide derivatives (Fig. 1) 
was performed as reported previously (Oltenfreiter et al., 2004; O'Brien et al., 2000; Hanessian et al., 2001; 
Oltenfreiter et al., 2005b) 4'-iodo-biphenyl was purchased from Daniels Fine Chemicals Ltd. (Edmonton, Alb., 
Canada) and used for synthesis of the non-radioactive analogues. 
2.2.   Radio synthesis 
The tracers were purified using an Alltech Alltima C18 column (250 x 4.6 mm, 5 µm) and a Gilson 307 pump. 
The eluate was monitored with an UV-VIS detector at λ = 254 nm (2487 dual λ absorbance detector, Waters) and 
a NaI detector (Bicron FrisktechTM, probe 1 X 1 inch). The obtained radioactive solution was dissolved in 
ethanol/water (200 µL, 5/95) and 740 kBq (20 µCi) of tracer was injected for in vivo biodistribution 
experiments. 
Fig. 1: Structure of the synthesized organic compounds. 
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2.2.1.  2-(4'-[123I]iodo-biphenyl-4-sulphonylamino )-3-methyl-butyric acid (1') 
To a solution of the tributylstannyl precursor (622 µg, 1 µmol) in ethanol (130 µL), n.c.a. [123I]NaI in sodium 
hydroxide solution (15 µL 0.05 M), chloramine T (1 µL, 0.1 M solution) and glacial acetic acid (5µL) were 
added respectively and the resulting mixture was stirred for 5 min at RT. The reaction mixture was quenched by 
addition of sodium metabisulfite (1 µL, 0.2 M solution). The mixture was purified by HPLC with 
ethanol/phosphate buffer (0.05 M, pH 2) (49/51) as mobile phase at a flow rate of 1 mL/min. The radiolabeled 
product was collected (Rt 29.97 min) and analysed with the same HPLC system. The radiochemical yield was 70 
± 5% (n=6), the radiochemical purity >98% and the specific activity >50Ci/µmol. 
2.2.2.  2-(4'-[123I] iodo-biphenyl-4-sulphonylamino)-3-methyl-butyramide (2') 
To a solution of 2-(4' -tributylstannyl-biphenyl-4-sulphony-lamino)-3-methyl-N-trityloxy-butyramide (400 µg, 
0.45 µmol) in ethanol (130 µL), n.c.a. [123I]NaI in sodium hydroxide solution (15 µL, 0.05 M), chloramine T (1 
µL, 0.1 M solution) and glacial acetic acid (5 µL) were added, respectively, and the resulting mixture was stirred 
for 5 min at RT. The reaction mixture was quenched by addition of sodium metabisulfite (1 µL, 0.2 M solution). 
The resulting mixture of radiolabeled product was analyzed by HPLC with ethanol/ phosphate buffer (0.05 M, 
pH 6) (70/30) as mobile phase at a flow rate of 1 mL/min (Rt 22.5min). In a one-pot reaction, trifluoroacetic acid 
(30 µL) was added to 2-(4'-[123I] iodo-biphenyl-4-sulphonylamino)-3-methyl-N-trityloxy-butyramide and stirred 
for 1 h to obtain compound 2'. This second mixture was purified under the same HPLC conditions using an 
ethanol/phosphate buffer (0.05 M, pH 6) (46/54) as mobile phase. The radiolabeled product 2' was collected (Rt 
20.69 min) and analyzed with the same HPLC system. The radiochemical yield was 60 ± 5% (n = 4), the 
radiochemical purity >98% and the specific activity >50Ci/ µmol. 
2.2.3.   Human serum albumin 
Radioiodination of human serum albumin (HSA) with 123I (Nordion Europe, Belgium) was performed by 
electrophilic substitution using the Iodogen technique. Briefly: in the Iodogen vial, 123I (111 MBq; 3mCi) was 
added to HSA (50 µg) in 140 µl 0.1 M potassium phosphate buffer at pH 8.5. After 15 min at room temperature, 
the mixture was removed from the Iodogen coated vial to stop the reaction. To remove the free 123I from [123I]-
iodo-HSA, the mixture was applied to a 0.22 µm Ag-filter. The specific activity was 1.5 x 105GBq/mmol 
(4Ci/µmol). Quality control was achieved using a standard prepacked PD-10 SEC column (Size Exclusion 
Chromatography, Amersham Pharmacia Biotech, Sweden) using PBS/HSA as the eluting agent. 
2.3.   In vitro enzyme assays of sulphonamide analogues 
2.3.1.   Enzymes 
The recombinant catalytic domain of MT1-MMP(cMTl), MT3-MMP(cMT3) and pro-MMP-2 were produced in 
Liège (Lang et al., 2004). Pro-MMP-9 was purchased from R&D Systems. Activation of pro-MMP-2 and pro-
MMP-9 was achieved by incubating pro-MMP-2 with 1 mM 4-aminophenylmercuric acetate (APMA) at 25 °C 
for 2 h and for pro-MMP-9 at 37 °C for 16 h. The solutions were divided into aliquots and frozen at -20 °C until 
needed. 
2.3.2.   Inhibition assay 
All kinetic measurements were performed in Tris/HCl 50mM pH 7.5, CaCl2 10 mM, Brij 35 0.05%. For each 
enzyme (MMP-2; cMT1; cMT3; MMP-9) the initial rate of cleavage of the fluorescent substrate Mca-Pro-Leu-
Gly Leu-Dpa-Ala-Arg-NH2 (5 µM for MMP-2 and cMT3 and 3 µM for cMT1 and MMP-9) was measured over 
15-20 min in the absence and presence of the inhibitor at different concentrations. The percentages of inhibition 
(% of inhibition) at the different inhibitor concentrations were calculated. IC50 values were obtained as 
previously described (O'Brien et al., 2000; Oltenfreiter et al., 2005b; Liabakk et al., 1996). 
2.4.   RT PCR analysis 
The expression profile of gelatinase A and gelatinase B was determined in several human breast carcinoma cell 
lines (SKBR3, MDA-MB231), a mouse mammary carcinoma EF43.fgf-4 (Hajitou et al., 1998), a pancreas 
carcinoma (Aspc-1), a non small cellular lung carcinoma (A549), a fibrosarcoma (HT1080) and A2058, a human 
melanoma cells transfected with MT1-MMP cDNA (S.I.5 clone) or control vector (CIV.3 clone). Analysis was 
performed as described previously (Goffin et al., 2003) using RNeasy Protect Kit and QIAshredder Kit 
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(QIAGEN Benelux, Venlo, Netherlands). On the basis of the results obtained, a suitable cell line to inoculate 
into athymic mice was chosen. 
2.5.   Zymography 
2.5.1.   Tumor extracts 
Tumors were freshly frozen in -80 °C. Proteins were extracted using 0,1 M Tris-HCl, pH 8.1+4% Triton and 
using Ureum 2M. The homogenate was centrifuged at 2000g for 20 min at 4°C and the supernatant stored at       
-80°C (Remacle et al., 2000). 
2.5.2.   Zymography 
Gelatinase (MMP-2 and MMP-9) activity was detected in tumor cytosols by gelatin zymography as previously 
described (Fabunmi et al., 1996), 15µg of protein were electrophoresed through a 4% polyacrylamide stacking 
gel and a 10% polyacrylamide separating gel, containing 1 mg/ ml gelatin (Sigma, St. Louis, MO) using a Bio-
Rad (Hercules, CA) Mini Protean II electrophoresis system. After electrophoresis, gels were incubated for 16 h 
in 50mM Tris-HCl (pH 8.0), 150mMNaCl, 5mMCaCl2, 0.05% NaN3 at 37 °C. Gels were stained in 25% 
methanol, 7% acetic acid in H2O containing 0.1% Coomassie Brilliant Blue R250 (Biorad) and destained in the 
same solution in the absence of dye. Gelatinases were detected as transparent bands on the blue background of 
the stained gel. 
2.6. Animal experiments 
All animals were treated according to the regulations of the Belgian law and the local Ethical Committee. The 
guidelines of the National Institute of Health principles of laboratory animal care (NIH publication 86-23, 
revised 1985) were followed. 
2.6.1.   Tumor model 
Three-week-old male Swiss nu/nu mice were inoculated subcutaneously in the right flank (armpit region) with 5 
x 106 A549 cells. When the tumor reached a volume of approximately 1 cm3 (3-4 weeks), the mice were used for 
biodistribution studies and planar imaging experiments. 
2.6.2.   Biodistribution studies 
Tumor bearing mice (n = 3) were injected intravenously in the tail vein with 740 kBq (20 µCi) of tracer. At 3, 6, 
9, 15, 24 and 48 h post injection mice were sacrificed by decapitation under halothane anaesthesia, their tissues 
excised, dried, weighed and counted for radioactivity with a Cobra automated gamma counter (Cobra II Series, 
Canberra Packard, Meriden, CT, USA Cobra). The injected dose (ID) was calculated by weighing the syringes 
before and after injection of the tracer and by the use of a dilution series of the injected tracer solution which was 
also weighed and counted for radioactivity. The concentration of radioactivity was decay corrected and 
expressed as a percentage of the injected dose per gram (%ID/g). 
2.6.3.   Metabolite analysis in blood 
NMRI mice (n = 3) were injected with approximately 1850kBq ( ± 50µCi) tracer i.v. in the tail vein. Mice were 
sacrificed 2h p.i. and blood samples were collected. The samples were centrifuged for 15 min at 6000g and the 
plasma was separated from the pellet. 1500 µL of acetoni-trile was added per g of pellet, the mixture was 
ultrasonicated and vortexed for 15-20min followed by centrifugation for 10min at 6000g. The combined 
supernatant fraction was centrifuged again for 10min at 6000g and 750 µL was processed by HPLC using an 
Alltech Econosil C18 column (250 x10 mm; 10 µm) and 60/40 acetonitrile/phosphate buffer (0.025 M, pH 2) as 
eluent at a flow rate of 2mL/min for 1'. For compound 2', 60/ 40 acetonitrile/phosphate buffer (0.025 M, pH 4) at 
a flow rate of 2 mL/min was used. The eluate was collected in fractions of 1 mL ( = 0.5min). These fractions 
were then counted for radioactivity on a Cobra automated gamma counter. To validate the extraction procedure, 
blood was taken from non-injected mice (n = 3) and spiked with 1 µCi of the labeled compound. The spiked 
controls underwent the same extraction procedure as mentioned above. Pellet and supernatant were counted for 
radioactivity in a gamma counter. The extraction yield was expressed as percentage of total radioactivity 
recovered in the supernatant. 
Published in: Applied Radiation & Isotopes (2006), vol.64, iss.6, pp.677-685 
Status: Postprint (Author’s version) 
2.6.4.   Metabolite analysis in tumor tissue 
Per gram of tissue, 1500 µL of acetonitrile was added. The sample was mixed for 30 s and centrifuged for 3 min 
at 6000g. 750 µL of the supernatant was processed on a HPLC system as described above for the appropriate 
compounds (n = 3). 
2.6.5.   Planar imaging 
Planar gamma camera imaging was performed in nu/nu athymic mice bearing a A549 tumor using a Toshiba 
GCA-9300A/hg camera, equipped with a high-resolution parallel-hole collimator. All images were acquired into 
256 x 256 matrices (FOV: 23.5 x 12.46 cm), with a photopeak window set at 15% around 159 keV and 
processed with a Hermes image processing system. 
Before tracer experiments were started, a [123I]-HSA study was performed to measure the relative blood pool 
distribution in order to correct the uptake of the labeled organic compounds in the tumor area as well as the rest 
of the animal for bloodpool activity. Ten tumor bearing mice were injected with 7.4 MBq [123I]-HSA and for 
each mouse ten dynamic planar images of 1 min were acquired, starting at 10 min after injection. Regions of 
interest (ROIs) were drawn around the tumor area and the contralateral background area. The tumor to 
contralateral background (RTB) ratios were calculated and the mean for all animals was determined. 
Mice (n = 3) were injected intravenously with approximately 37 MkBq (= 1 mCi) tracer (1'; 2') in the tail vein. 
To optimize scan time for planar scintigraphy imaging, animals were scanned at 6, 24 and 48 h post i.v. tracer 
injection. During all imaging experiments, the animals were anesthetized by intraperitoneal injection (IP) of 75 
µl of a solution containing 20 mg pentobarbital per ml (Nembutal, 60 mg/ml, Ceva Santé Animale, Belgium) and 
placed in the prone position in a sterile cage with filter top to preserve sterility during imaging. ROIs were 
drawn, RTBs were calculated and corrected for blood pool activity. By decreasing the specific activity of 1' we 
tried to decrease liver uptake, indicating some degree of saturable binding of the tracer in the liver and resulting 
in better images. 
3. Results 
The IC50 values of (1,2) for MMP-2, MMP-9, cMT1 and cMT3 are expressed in nM and averaged (n = 3), 
standard deviations are also reported. For compound 1 IC50 values were 23 ± 3 M, 429 ± 36nM; 180 ± 45nM and 
232 ± 29 nM, respectively, and for compound 2 in 48 ± 2; 740 ± 62; 2509 ± 342; 973 ± 150. The expression 
profiles of gelatinase A, gelatinase B in several breast carcinoma cell lines (SKBR3, MDA-MB231, EF43.fgf-4), 
pancreas carcinoma (Aspc-1), non small cellular lung carcinoma (A549), fibrosarcoma (HT1080) and A2058 
human melanoma cells transfected with MT1-MMP cDNA (S.I.5 clone) or control vector (C.IV.3 clone) are 
shown in Fig. 2. Zymography on tumors grown in mice was performed and showed expression of both 
gelatinases (Fig. 3). Based on the results obtained, the A549 cell line was used for in vivo experiments. 
Table 1: Tissue concentrations of radioactivity at various time points post i.v. administration of 2-(4'-[123I] iodo-
biphenyl-4-sulphonylamino)-3-methyl-butyric acid (1')a in A549 inoculated mice 
 Time (h) 
 3 6 9 15 24 48 
Blood 5.93 ± 1.24 6.11 ± 2.99 6.32 ± 1.28 3.70 ± 1.33 3.31 ± 1.54 1.44 ± 0.49 
Liver 44.86 ± 24.25 26.04 ± 7.28 28.89 ± 5.54 15.91 ± 2.58 19.62 ± 2.99 8.45 ± 1.96 
Small intestines 3.91 ± 0.48 4.54 ± 1.42 4.48 ± 1.2 2.69 ± 0.97 2.54 ± 0.86 1.14 ± 0.32 
Large intestines 2.43 ± 0.27 4.33 ± 1.64 5.65 ± 2.52 3.81 ± 2.90 3.11 ± 1.20 1.76 ± 0.77 
Kidneys 8.44 ± 2.93 6.97 ± 3.76 6.92 ± 1.55 4.17 ± 1.65 4.15 ± 1.29 1.40 ± 0.28 
Stomach 0.56 ± 0.36 0.87 ± 0.51 0.61 ± 0.07 0.56 ± 0.36 0.87 ± 0.38 0.50 ± 0.41 
Muscle 0.79 ± 0.65 0.52 ± 0.24 0.48 ± 0.11 0.34 ± 0.07 0.32 ± 0.18 0.16 ± 0.07 
Tumor 2.00 ± 0.40 1.83 ± 0.42 1.88 ± 0.34 1.52 ± 0.59 1.33 ± 0.79 0.75 ± 0.44 
Fat 2.65 ± 2.18 1.76 ± 1.06 1.23 ± 0.42 0.75 ± 0.18 0.96 ± 0.71 0.37 ± 0.08 
Tumor/blood 0.34 0.30 0.3 0.41 0.40 0.52 
Tumor/muscle 2.52 3.51 3.92 4.44 4.13 4.63 
aAnimals were injected intravenously with 740 kBq [123I] 2-(4'-[123I] iodo-biphenyl-4-sulphonylamino)-3-methyl-butyric acid (1') and 
sacrificed at designated times. Units are expressed as % injected dose/g of tissue (n = 3) corrected for background radiation and averaged. 
Below are reported the standard deviations. 
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Fig. 2: The expression profile of gelatinase A and gelatinase B in several breast carcinoma cell lines (SKBR3, 
MDA-MB231, EF43fgf4), pancreas carcinoma (Aspc-1), lung carcinoma (A549), fibrosarcoma (HT1080) and 
A2058 human melanoma cells transfected with MT1-MMP cDNA (S.I.5 clone) or control vector (C.IV.3 clone). 
 
 
Fig. 3: Proteins were extracted using 0.1 M Tris-HCl, pH 8.1 +4% Triton (A) and using Ureum 2M (B). The 
homogenate was centrifuged at 2000g for 20min at 4°C and the supernatant stored at - 80 °C. Zymography was 
performed as described in Section 2. 
 
 
In vivo experiments showed a tumor uptake of 2.0 ± 0.4%ID/g at 3hp.i. decreasing to 0.8 ± 0.4%ID/g at 48hp.i., 
a tumor/blood ratio of 0.5 and a tumor/muscle ratio of 4.6 at 48 hp.i. for compound 1'. For compound 2' a tumor 
uptake of 0.7 ± 0.1%ID/g at 3hp.i. decreasing to 0.2 ± 0.1%ID/g at 48 hp.i., a tumor/blood ratio of 1.04 and a 
tumor/muscle ratio of 1.57 at 48h p.i. was observed (Table 1 (1') and Table 2 (2')). 
HPLC analysis of the mouse plasma (extraction yields for 1' and 2' ≥ 90%) showed no dehalogenation of 1' 2 h 
post injection. No other metabolites were detected. Therefore, the high liver uptake was not caused by 
metabolisation. For compound 2', 65.4% of intact compound was found in the blood and only one polar 
metabolite (31%) was detected. In the tumor 91.8% of the detected activity was represented by the intact 
compound and only 8.1% by a metabolite (Fig. 4). 
The ratio between the blood flow in the tumor and the contralateral reference leg using [123I]-HSA resulted in 
RTB = 1.2 ± 0.03, indicating a significant higher blood pool in tumor than in reference leg. 2-(4'-[123I] iodo-
biphenyl-4-sulphonylamino)-3-methyl-butyric acid (1') and 2-(4'-[123I] iodo-biphenyl-4-sulphonylamino)-3-
methyl-bu-tyramide (2') gave a slightly visible tumor uptake which was more defined when reducing specific 
activity of compound 1' (Fig. 4) resulting in lower liver uptake, thus indicating some degree of saturable binding 
of the tracer in the liver. ROIs were drawn, RTB and correction for bloodpool activity were calculated resulting 
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in the following ratio's: 2.18 ± 0.65; 1.65 ± 0.48; 1.85 ± 0.15 for compound 1' at 6, 24 and 48 h post injection, 
respectively. For compound 2' the corresponding ratios were 1.42 ± 0.31; 1.78 ± 0.17; 2.09 ± 0.38 at 6, 24 and 48 
h post injection. An image with reduced specific activity of 1' revealed no better RTB ratios: (1.40 ± 0.13; 1.62 ± 
0.37; 1.58 ± 0.31) but image quality was improved by reduced liver uptake (a decrease from 44.86 ± 24.25%ID/g 
3hp.i. to 12.09 ± 1.94 3hp.i.) (Fig. 5). 
 
Fig. 4: Metabolite analysis in blood, tumor of 1' (A, C) and 2' (B, D). 
 
 
Table 2: Tissue concentrations of radioactivity at various time points post i.v. administration of 2-(4'-[123I] iodo-
biphenyl-4-sulphonylamino)-3-methyl-butyramide (2')a in A549 inoculated mice 
 Time (h) 
 3 6 9 15 24 48 
Blood 2.31±0.44 1.67 ± 0.42 1.20 ± 0.28 0.49 ± 0.17 0.36 ± 0.08 0.17 ± 0.04 
Liver 4.02 ± 0.61 3.78±0.28 3.29 ± 0.20 1.98 ± 1.06 1.87 ± 1.07 0.84 ± 0.22 
Small intestines 5.6 ± 2.88 3.37 ± 1.48 2.19 ± 0.71 1.4 ± 0.65 0.91±0.29 0.46 ± 0.09 
Large intestines 29.66 ± 3.47 11.81 ± 4.51 5.96 ± 3.05 2.84 ± 2.39 1.25 ± 0.38 0.87 ± 0.38 
Kidneys 3.69 ± 0.60 3.68±0.44 3.04 ± 0.62 1.46 ± 0.68 0.97 ± 0.37 0.46 ± 0.23 
Stomach 0.67 ± 0.25 1.11±0.16 0.68 ± 0.15 0.51±0.29 0.50 ± 0.34 0.42 ± 0.05 
Muscle 0.49 ± 0.1 0.47 ± 0.07 0.49 ± 0.05 0.36 ± 0.21 0.24 ± 0.1 0.11 ± 0.03 
Tumor 0.71±0.08 0.80 ± 0.1 0.83 ± 0.05 0.53±0.23 0.44 ± 0.15 0.17 ± 0.08 
Fat 1.03 ± 0.23 0.81±0.12 1.09 ± 0.20 0.51±0.16 0.31±0.11 0.12 ± 0.06 
Tumor/blood 0.31 0.48 0.69 1.07 1.23 1.04 
Tumor/muscle 1.45 1.70 1.67 1.48 1.82 1.57 
aAnimals were injected intravenously with 740 [123I] 2-(4'-[123I] iodo-biphenyl-4-sulphonylamino)-3-methyl-butyramide (2')a and sacrificed at 
designated times. Units are expressed as % injected dose/g of tissue (n = 3) corrected for background radiation and averaged. Below are 
reported the standard deviations. 
 
Published in: Applied Radiation & Isotopes (2006), vol.64, iss.6, pp.677-685 
Status: Postprint (Author’s version) 
Fig. 5: (A) planar scintigraphy imaging for compounds 1' and 2', respectively at 6; 24 and 48 h post i.v. tracer 
injection. Tumor position is pointed with an arrow. (B) Planar scintigraphy imaging for compound 1' at 24 h 
post i.v. tracer injection, with reduced specific activity. Tumor position is pointed with an arrow, for scaling 




The MMPIs all share a common scaffold: a peptidomimetic backbone that interacts with "substitutes" 
surrounding the active site coupled to a metal chelator (zinc-binding group) that binds to the catalytic Zn(II) ion. 
To improve the selectivity of MMPIs, this backbone is substituted with side chains that interact with specific 
pockets within the active domain of the MMPs (Fei et al., 2003). The S1' subsite for the gelatinases is relatively 
deeper than for other subtypes and is targeted to obtain highly selective inhibitors. A sulphonamide group is 
incorporated in the inhibitor to improve the enzyme-inhibitor binding not only by forming hydrogen bonds to the 
enzyme but also by properly directing the hydrophobic substituent to the S1' subsite and enabling it to plunge in 
deeply (Kiyama et al., 1998). The biphenyl function is incorporated to improve selectivity towards gelatinases. 
Tryptophane-based biphenylsulphonamide matrix metalloproteinase inhibitors were synthesized, evaluated in 
vitro; in vivo and as imaging agents and published previously [14]. Structural changes to the biphenyl ring 
system, in the αposition to carboxylic/hydroxamic acid, and to the carboxylate moiety have an influence on 
biological activity, selectivity and pharmacokinetic properties. Accordingly, we developed valine-based 
biphenylsulphonamide matrix metalloproteinase inhibitors, which were evaluated in the current paper. The IC50 
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values of all synthesized analogues were in the nanomolar range and thus suitable for in vivo imaging. There 
was, however, a distinction between the valine and the earlier published tryptophane derivatives, namely that 
both hydroxamic and carboxylic acid Valine compounds showed a higher selectivity for MMP-2 in comparison 
to the Tryptophane analogues, which is probably reflected in a different inhibition of tumor invasiveness due to 
the importance of especially MMP-2. Metabolite analysis revealed a lower dehalogenation of valine analogues, 
probably resulting in higher tumor uptake and slightly better images, whereas with tryptophane only a high 
abdominal uptake could be detected while a lower tumor uptake was detected. As for both compounds no or less 
metabolites are present in tumor tissue and uptake in the tumor could not be attributed to blood pool activity, the 
blinding of the evaluated MMPIs may be specific and there could be a future for other small organic MMP 
inhibitors. Acceptable tumor uptake of valine compounds combined with the relatively rapid wash-out from 
normal tissues, excluding the liver, should allow for straightforward imaging of tumors and thus support the 
theoretical suitability of these tracers in vivo. The results have shown however that other parameters must be 
looked at, and that the discrepancy between encouraging in vitro results and in vivo results (rather low tumour 
uptake and doubtful use as imaging agent) was also evidenced by others and remains to be elucidated (Zheng et 
al., 2004; Zheng et al., 2003; Furumoto et al., 2003). 
So far, it it has been difficult to use MMPIs as tumor imaging agents, however, new analogues in combination 
with other tumour models are mandatory to better understand and evaluate MMPIs as imaging agents. 18F 
labeled analogues could be produced to obtain higher resolution of images. The possibility of visualizing tumors 
will also depend largely upon their MMP expression profile which varies over time. Thus, prior to clinical 
evaluation, additional research focusing on the influence of tumor stage, in various types of tumor models with 
known overexpression of MMPs, on uptake of newly synthesised analogues; as well as the relationship between 
tracer uptake and MMP expression is mandatory (Furumoto et al., 2003). 
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